Madrigal shares skyrocket on positive NASH treatment study results
December 19, 2022 at 09:36 AM EST
The Conshohocken company expects to seek approval for its treatment of an inflammatory liver disease during the first half of 2023.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|